SIGA Technologies, Inc.

SIGA

HealthcareSmall CapUS Equities · NYSE / NASDAQ

AI Agents

Company Profile

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. The company's lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. was incorporated in 1995 and is headquartered in New York, New York.

Valuation

Market Cap$325M

Current Price$4.53

P/E Ratio14.16

P/B Ratio1.63

EV / EBITDA7.02

EV / Sales1.80

Profitability

Operating Margin-

Net Profit Margin24.6%

EBITDA Margin25.7%

Returns

ROE11.7%

ROCE-

ROIC %40.9%

ROA10.6%

Solvency

Current Ratio11.83

Debt / Equity0.00

Debt / Assets0.00

CFO / Net Profit1.87

Price History▼ 21.35% over 1Y

Technical Chart

Historical Performance Charts

5-year financial trends. Figures in USD millions.

Revenue vs Net Profit (5Y)

Free Cash Flow vs Operating Cash Flow (5Y)

Operating Margin % (5Y)

Growth Summary

Latest fiscal year: 2025

Revenue$95M▼ 31.8%

EBITDA$24M

Net Profit$23M▼ 60.7%

Cash from Ops (CFO)$43M

Free Cash Flow (FCF)$43M

Revenue CAGR 3Y-

Revenue CAGR 5Y-

Net Profit CAGR 3Y-

Net Profit CAGR 5Y-

Historical Growth

Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)

Year	Revenue	EBITDA	Net Profit	FCF	ROE	Rev Growth 1Y	NP Growth 1Y
2025	$95M	$24M	$23M	$43M	11.7%	-31.8%	-60.7%
2024	$139M	$71M	$59M	$49M	27.4%	-0.9%	-13.0%
2023	$140M	$84M	$68M	$95M	34.6%	26.3%	100.8%
2022	$111M	$43M	$34M	$42M	19.9%	-	-

Financial Statements

Income statement, balance sheet, and cash flow as reported

Consolidated Figures in USD Millions.

Metric	2022	2023	2024	2025
Total Revenue	110.78	139.92	138.72	94.57
Cost Of Revenue	32.96	34.25	43.60	49.66
Gross Profit	77.82	105.66	95.12	44.91
Operating Expense	35.12	22.04	25.14	21.21
Operating Income	42.70	83.62	69.98	23.70
EBITDA	43.22	84.16	70.52	24.26
EBIT	42.70	83.62	69.98	23.70
Pretax Income	44.13	87.78	76.07	30.38
Tax Provision	10.23	19.71	16.86	7.10
Net Income	33.90	68.07	59.21	23.28
Net Income Common Stockholders	33.90	68.07	59.21	23.28
Total Expenses	68.08	56.30	68.74	70.87
Interest Expense	0	0	0	0
Research And Development	22.53	16.43	12.31	0
Selling General And Administration	35.12	22.04	25.14	21.21
Normalized EBITDA	42.82	84.16	70.52	24.26
Normalized Income	33.60	68.07	59.21	23.28
Basic EPS	0.46	0.95	0.83	0.33
Diluted EPS	0.46	0.95	0.82	0.32
Tax Effect Of Unusual Items	0.09	0	0	0
Tax Rate For Calcs	0.23	0.23	0.22	0.23
Total Unusual Items	0.40	0	0	0
Total Unusual Items Excluding Goodwill	0.40	0	0	0
Net Income From Continuing Operation Net Minority Interest	33.90	68.07	59.21	23.28
Reconciled Depreciation	0.52	0.54	0.54	0.56
Reconciled Cost Of Revenue	32.96	34.25	43.60	49.66
Net Interest Income	0	0	0	0
Net Income From Continuing And Discontinued Operation	33.90	68.07	59.21	23.28
Total Operating Income As Reported	42.70	83.62	69.98	23.70
Diluted Average Shares	73.55	71.68	71.91	71.87
Basic Average Shares	72.93	71.36	71.25	71.53
Diluted NI Availto Com Stockholders	33.50	68.07	59.21	23.28
Average Dilution Earnings	-0.40	0	0	0
Net Income Including Noncontrolling Interests	33.90	68.07	59.21	23.28
Net Income Continuous Operations	33.90	68.07	59.21	23.28
Other Income Expense	1.43	4.16	6.09	6.68
Other Non Operating Income Expenses	1.03	4.16	6.09	6.68
Special Income Charges	0	0	0	0
Gain On Sale Of Security	0.40	0	0	0
Net Non Operating Interest Income Expense	0	0	0	0
Interest Expense Non Operating	0	0	0	0
Other Operating Expenses	0	0	0	0
Operating Revenue	110.78	139.92	138.72	94.57

Peer Comparison

Healthcare sector peers, ranked by market cap

Company	Ticker	Market Cap	P/E	P/B	ROE	EV/EBITDA
SIGA Technologies, Inc.this co.	SIGA	$325M	14.16	1.63	11.7%	7.02
Standard BioTools Inc.	LAB	$346M	-	0.81	-17.7%	-2.30
Evolus, Inc.	EOLS	$337M	-	-14.59	223.5%	-14.56
Monopar Therapeutics Inc.	MNPR	$335M	-	2.43	-10.0%	-
Cross Country Healthcare, Inc.	CCRN	$331M

Learn while you research

Hand-picked academy chapters to deepen your understanding of SIGA Technologies, Inc. and the metrics that matter.

01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read 02 Stock Market Risks

Loading…

Year

Revenue

EBITDA

Net Profit

FCF

ROE

Rev Growth 1Y

NP Growth 1Y

2025

$95M

$24M

$23M

$43M

11.7%

-31.8%

-60.7%

2024

$139M

$71M

$59M

$49M

27.4%

-0.9%

-13.0%

2023

$140M

$84M

$68M

$95M

34.6%

26.3%

100.8%

2022

$111M

$43M

$34M

$42M

19.9%

Metric

2022

2023

2024

2025

Total Revenue

110.78

139.92

138.72

94.57

Cost Of Revenue

32.96

34.25

43.60

49.66

Gross Profit

77.82

105.66

95.12

44.91

Operating Expense

35.12

22.04

25.14

21.21

Operating Income

42.70

83.62

69.98

23.70

EBITDA

43.22

84.16

70.52

24.26

EBIT

42.70

83.62

69.98

23.70

Pretax Income

44.13

87.78

76.07

30.38

Tax Provision

10.23

19.71

16.86

7.10

Net Income

33.90

68.07

59.21

23.28

Net Income Common Stockholders

33.90

68.07

59.21

23.28

Total Expenses

68.08

56.30

68.74

70.87

Interest Expense

Research And Development

22.53

16.43

12.31

Selling General And Administration

35.12

22.04

25.14

21.21

Normalized EBITDA

42.82

84.16

70.52

24.26

Normalized Income

33.60

68.07

59.21

23.28

Basic EPS

0.46

0.95

0.83

0.33

Diluted EPS

0.46

0.95

0.82

0.32

Tax Effect Of Unusual Items

0.09

Tax Rate For Calcs

0.23

0.22

0.23

Total Unusual Items

0.40

Total Unusual Items Excluding Goodwill

0.40

Net Income From Continuing Operation Net Minority Interest

33.90

68.07

59.21

23.28

Reconciled Depreciation

0.52

0.54

0.56

Reconciled Cost Of Revenue

32.96

34.25

43.60

49.66

Net Interest Income

Net Income From Continuing And Discontinued Operation

33.90

68.07

59.21

23.28

Total Operating Income As Reported

42.70

83.62

69.98

23.70

Diluted Average Shares

73.55

71.68

71.91

71.87

Basic Average Shares

72.93

71.36

71.25

71.53

Diluted NI Availto Com Stockholders

33.50

68.07

59.21

23.28

Average Dilution Earnings

-0.40

Net Income Including Noncontrolling Interests

33.90

68.07

59.21

23.28

Net Income Continuous Operations

33.90

68.07

59.21

23.28

Other Income Expense

1.43

4.16

6.09

6.68

Other Non Operating Income Expenses

1.03

4.16

6.09

6.68

Special Income Charges

Gain On Sale Of Security

0.40

Net Non Operating Interest Income Expense

Interest Expense Non Operating

Other Operating Expenses

Operating Revenue

110.78

139.92

138.72

94.57

Company

Ticker

Market Cap

P/E

P/B

ROE

EV/EBITDA

SIGA Technologies, Inc.this co.

SIGA

$325M

14.16

1.63

11.7%

7.02

Standard BioTools Inc.

LAB

$346M

0.81

-17.7%

-2.30

Evolus, Inc.

EOLS

$337M

-14.59

223.5%

-14.56

Monopar Therapeutics Inc.

MNPR

$335M

2.43

-10.0%

Cross Country Healthcare, Inc.

CCRN

$331M

SIGA Technologies, Inc.

Valuation

Profitability

Returns

Solvency

Historical Performance Charts

Revenue vs Net Profit (5Y)

Free Cash Flow vs Operating Cash Flow (5Y)

Operating Margin % (5Y)

Growth Summary

Historical Growth

Financial Statements

Peer Comparison

SIGA Technologies, Inc.

Valuation

Profitability

Returns

Solvency

Historical Performance Charts

Revenue vs Net Profit (5Y)

Free Cash Flow vs Operating Cash Flow (5Y)

Operating Margin % (5Y)

Growth Summary

Historical Growth

Financial Statements

Peer Comparison

Key concepts to brush up on